

1 **De Novo Phosphoinositide Synthesis in Zebrafish Is Required for**
2 **Triad Formation but Not Essential for Myogenesis**

3

4 Lindsay Smith^{1,2}, Lacramioara Fabian¹, Almundher Al-Maawali^{1,3}, Ramil R. Noche⁴,
5 James J. Dowling^{1,5,6*}

6

7 ¹ Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto,
8 Ontario, Canada

9 ² Ontario Institute for Cancer Research, Toronto, Ontario, Canada

10 ³ Department of Genetics, College of Medicine and Health Sciences, Sultan Qaboos
11 University & Sultan Qaboos University Hospital , Muscat, Oman

12 ⁴ Zebrafish Genetics and Disease Models Core Facility, The Hospital for Sick Children,
13 Toronto, Ontario, Canada

14 ⁵ Division of Neurology, The Hospital for Sick Children, Toronto, Ontario, Canada

15 ⁶ Departments of Paediatrics and Molecular Genetics, University of Toronto, Toronto,
16 Ontario, Canada

17

18

19

20 *Corresponding author:

21 Email: james.dowling@sickkids.ca (JJD)

22

23

24 **Abstract**

25 Phosphoinositides (PIPs) and their regulatory enzymes are key players in many cellular
26 processes and are required for aspects of vertebrate development. Dysregulated PIP
27 metabolism has been implicated in several human diseases, including a subset of
28 skeletal myopathies that feature structural defects in the triad. The role of PIPs in
29 skeletal muscle formation, and particularly triad biogenesis, has yet to be determined.
30 CDP-diacylglycerol-inositol 3-phosphatidyltransferase (CDIPT) catalyzes the formation
31 of phosphatidylinositol, which is the base of all PIP species. Loss of CDIPT should, in
32 theory, result in the failure to produce PIPs, and thus provide a strategy for establishing
33 the requirement for PIPs during embryogenesis. In this study, we generated *cdipt*
34 mutant zebrafish and determined the impact on skeletal myogenesis. Analysis of *cdipt*
35 mutant muscle revealed no apparent global effect on early muscle development.
36 However, small but significant defects were observed in triad size, with T-tubule area,
37 inter terminal cisternae distance and gap width being smaller in *cdipt* mutants. This was
38 associated with a decrease in motor performance. Overall, these data suggest that
39 myogenesis in zebrafish does not require *de novo* PIP synthesis but does implicate a
40 role for CDIPT in triad formation.

41 **Introduction**

42 The primary function of skeletal muscle is to produce the force that initiates and controls
43 movement. Muscle has a number of unique substructures that are dedicated to force
44 production, including the sarcomere, the neuromuscular junction (NMJ) and the triad
45 (Dowling et al., 2014). As our understanding of the molecular basis of human muscle
46 diseases grows, it is becoming more apparent that many myopathies involve alterations
47 to at least one of these structures (Dowling et al., 2014; Gonorazky et al., 2018; Nance
48 et al., 2012). Of increasing significance are the abnormalities in the structure and
49 function of the triad, which represents the apposition of the T-tubules and the terminal
50 cisternae of the sarcoplasmic reticulum (SR). The key role of the triad is to mediate
51 excitation-contraction coupling (EC coupling), the process by which skeletal muscle
52 translates neuronal signals into muscle contraction (Al-Qusairi and Laporte, 2011;
53 Jungbluth et al., 2018).

54 Although triad malformations are considered the major cause of muscle weakness in
55 many myopathies (Dowling et al., 2014), the factors that govern the development and
56 maintenance of the triad remain unclear. Recent data has suggested that
57 phosphoinositides may play an important role in triad formation and/or maintenance.
58 Phosphoinositides (PIPs) are a family of membrane phospholipids involved in many
59 essential cell functions, including cellular signaling, endocytosis, and autophagy, and
60 are present in almost all cell types across eukaryotic species (De Camilli et al., 1996)
61 (Balla, 2013). Formation and turnover of the various PIP species are catalyzed by
62 evolutionarily conserved families of kinases and phosphatases (De Matteis and Godi,
63 2004; Viaud et al., 2016). Dysregulation of PIPs and their metabolic enzymes have

64 been implicated in a number of human diseases, such as congenital myopathies,
65 Charcot-Marie-Tooth Disease (CMT), Alzheimer's disease, and some forms of cancer
66 (Bunney and Katan, 2010; Lo Vasco, 2018; Nicholson et al., 2011; Volpatti et al., 2019).

67 The consideration of a potential role for PIPs in muscle development comes from two
68 areas of study. One is the work surrounding BIN1, a BAR domain-containing protein
69 that is known to recognize and induce membrane curvature (Peter et al., 2004); (Frost
70 et al., 2009). BIN1 has a PIP-binding domain that interacts with PIP2 (one of the seven
71 PIP sub-species), and this interaction plays a critical role in the formation of T-tubules.

72 Recessive mutations in *BIN1* result in centronuclear myopathy, a severe congenital
73 muscle disease featuring abnormal muscle structure including disturbance of the T-
74 tubule and the triad as a whole. The second line of evidence comes from another form
75 of centronuclear myopathy called X-linked myotubular myopathy or XLMTM (Dowling et
76 al., 2009) (Amoasii et al., 2012). XLMTM is caused by mutations in the PIP
77 phosphatase myotubularin. Mutation in myotubularin causes accumulation of PI3P and
78 leads to abnormalities in the appearance and number of the triad.

79 In this study, we investigated the role of PIPs in skeletal muscle triad development using
80 the zebrafish model system. Zebrafish is an elegant model for studying skeletal muscle
81 development (Gibbs et al., 2013). Skeletal muscle develops rapidly in zebrafish, muscle
82 fibers are already developing by 24 hours post-fertilization (hpf), with elongated fibers
83 visible by 2 days post-fertilization (dpf). Skeletal muscle is highly prominent in embryos
84 and larvae, and the transparency of developing fish allows muscle fibers to be easily
85 observed. Additionally, zebrafish muscle shares many structural and histological
86 features with mammalian muscle.

87 To determine the overall requirement for PIPs in muscle development we used the
88 CRISPR/Cas9 technology to generate a *cdipt* zebrafish mutant. CDIPT, also known as
89 phosphatidylinositol synthase (PIS), catalyzes the addition of a *myo*-inositol ring to a
90 phospholipid backbone, cytidine diphosphate-diacylglycerol (CDP-DAG), to generate
91 the base of all PIPs, phosphatidylinositol (PI) (Lykidis et al., 1997) (Fig 1A). This is the
92 only protein currently known to perform this function in zebrafish (Thakur et al., 2011).
93 CDIPT is a highly conserved integral membrane protein found on the cytoplasmic side
94 of the endoplasmic reticulum (ER).

95

96 **Fig 1. Development of a CRISPR/Cas9 *cdipt* mutant zebrafish.**

97 **A)** Schematic representation of phosphoinositide signaling pathway. CDIPT
98 catalyzes the addition of the *myo*-inositol to the CDP-DAG to generate PI, which
99 is the base precursor for all species of PIPs. **B)** Schematic representing exon
100 organization of *cdipt*. Exon 3 was targeted by CRISPR/Cas9 gene editing. **C)**
101 Sanger sequencing of wildtype (WT) and homozygous *cdipt* mutant (MUT) larvae
102 showing a 10-bp deletion in exon 3 of *cdipt*. **D)** Fold change of mRNA levels
103 between WT and MUT fish at both 3 dpf and 6 dpf. There is a significant change
104 in *cdipt* mRNA levels between WT and MUT zebrafish at both 3 dpf (0.5-fold
105 reduction; *p=0.0035) and 6 dpf (0.6-fold reduction; **p=0.0073). Each replicate
106 is represented by a point, n = 30 per replicate; Student's *t* test, 2-tailed. Error
107 bars indicate SEM.

108

109 Previous study of a zebrafish *cdipt* mutant revealed a liver phenotype reminiscent of
110 phenotypes seen in other models of PIP dysregulation (Thakur et al., 2011). This study,
111 however, did not examine skeletal muscle. In the current study, we examine the skeletal
112 muscle in a new *cdipt* mutant. We show that loss of CDIPT has no effect on early
113 muscle development, suggesting that skeletal myogenesis does not require *de novo*
114 PIP synthesis. Instead, CDIPT appears to be required for proper formation of the triad.

115

116 **Materials and methods**

117

118 **Zebrafish maintenance**

119 Zebrafish stocks were maintained at the Zebrafish Facility at the Hospital for Sick
120 Children, Toronto, ON, Canada. All zebrafish procedures were performed in compliance
121 with the Animals for Research Act of Ontario and the Guidelines of the Canadian
122 Council on Animal Care.

123

124 **Generation of zebrafish *cdipt* mutants**

125 A detailed procedure for CRISPR/Cas9 editing in zebrafish has been described
126 previously (Ma et al., 2016). The *cdipt* target in this study was 5'-
127 GGTTCCACCAGCAAACACATGGTGG-3' in exon 3. One-cell-stage AB WT embryos
128 were injected with gRNA and Cas9 mRNA with a Picopump (World Precision
129 Instruments). Potential founders (F₀) were outcrossed to AB WT fish. Genomic DNA
130 was isolated from single F₁ embryos at 6 dpf and genotyped using high resolution melt
131 (HRM) analysis. A *cdipt* sequence spanning the CRISPR/Cas9 target site was amplified
132 with the following primers: F: 5'-AGCTGGAACAGAAAAGTGTAGGA-3'; and R: 5'-
133 TAGGTACAAAATTTGGTGCAATG-3'. Carriers were identified and outcrossed
134 ultimately to the F₃ generation. In-cross progeny from the F₃ and F₄ generations were
135 characterized in this study.

136

137 **Real-time PCR (qPCR)**

138 RNA was extracted from 3 dpf and 6 dpf *cdipt* mutant zebrafish and their wildtype
139 siblings using RNAeasy (Qiagen). RNA samples were reverse transcribed into cDNA
140 using the iScript cDNA synthesis kit (BioRad). Primers were designed to result in a
141 product spanning exons 4-6 of *cdipt*: F: 5'-ACCCCATTTTACGGCTGTACT-'3; and R:
142 5'-TACCTGGGGTTCTTCGATGT-'3. Products were amplified using Step-One-Plus
143 Real-Time PCR System (Applied Biosystems). The zebrafish beta-actin gene, *actb1*,
144 was used as an endogenous control.

145

146 **Birefringence**

147 Tricaine-anaesthetised larvae were mounted in 3% methylcellulose on glass slides and
148 imaged under polarized light on a dissecting microscope (Olympus SZX7).

149

150 **Skeletal myofiber preparations**

151 Myofiber preparations of 6 dpf wildtype and *cdipt* mutant zebrafish were made following
152 the protocol described previously (Horstick et al., 2013).

153

154 **Immunofluorescence staining**

155 Immunostaining of myofiber preparations was performed as previously described
156 (Horstick et al., 2013). Briefly, myofiber preparations were fixed with 4% PFA, for 20

157 min, permeabilized with PBST (0.3% TritonX in PBS), blocked for 1 hour with PBSTB
158 (5% BSA in PBT) and incubated overnight at 4°C with primary antibodies. The following
159 primary antibodies were used: mouse anti-DHPR (1:200; DHPRa1A; Abcam), mouse
160 anti- α -Actinin (1:100; Sigma), mouse anti-RyR1 (1:100; 34C; DSHB), rabbit anti-Junctin
161 (1:350; gift from Dulhunty lab), mouse anti-PI(3)P (1:100; Echelon Biosciences Inc.),
162 mouse anti-PI(3,4)P2 (1:100; Echelon Biosciences Inc.), mouse anti-PI(4,5)P2 (1:100;
163 Echelon Biosciences Inc.). Alexa Fluor-conjugated secondary antibodies were used at
164 1:1000 (Invitrogen). Rhodamine phalloidin (Phalloidin 555) was used to visualize
165 filamentous actin (1:300, Molecular Probes). Preparations were mounted with ProLong
166 Gold with DAPI (Invitrogen). Images were acquired with a Nikon Eclipse Ti laser
167 scanning confocal using NIS Elements software (company, location) and only adjusted
168 for brightness and contrast using Adobe Photoshop.

169

170 **Live confocal imaging**

171 One-cell stage zebrafish embryos were injected with 10 pg of a cDNA construct
172 containing a fluorescent protein attached to a PIP-binding protein domain [Bodipy-PI
173 (Echelon Biosciences Inc)]; PLC- β -PH-GFP (Tobias Meyer Lab, Stanford University,
174 CA) using a Picopump (World Precision Instruments). At 1 dpf, injected zebrafish were
175 incubated in 0.2 mM phenylthiourea to prevent pigment formation. To image, zebrafish
176 were screened for fluorescent myofibers on a macroscope (Zeiss Axio Zoom) and
177 mounted in 1.5% low-melt agarose on a 3 cm glass-bottom petri dish. All confocal

178 images were taken with a Nikon Eclipse Ti confocal microscope using a 40x oil-
179 immersion lens.

180

181 **Transmission electron microscopy**

182 Zebrafish clutches at 6 dpf were anaesthetised in tricaine and fixed in Karnovsky's
183 fixative overnight at 4°C. Samples were sent to the Advanced Bioimaging Center
184 (Sickkids Peter Gilgan Centre for Research and Learning, Toronto) where larvae were
185 processed. Briefly, larvae were rinsed in buffer, post-fixed in 1% osmium tetroxide in
186 buffer, dehydrated, and embedded in Quetol-Spurr resin. Following this, 70 nm sections
187 thick were cut with a Leica UC7 ultramicrotome, stained with uranyl acetate and lead
188 citrate, and viewed either with an FEI Tecnai 20 transmission electron microscope
189 (Tecnai, Oregon, USA) (Bioimaging Facility at The Hospital for Sick Children, Toronto)
190 or with a JEOL JEM 1200EX TEM (JEOL, Massachusetts, USA) (Electron Microscopy
191 Facility at the Laboratory of Pathology, The Hospital for Sick Children, Toronto). Images
192 were obtained using Gatan Digital Micrograph acquisition software or AmtV542, and
193 were manipulated only for brightness and contrast using Adobe Photoshop.

194

195 **Immuno-electron microscopy**

196 6 dpf zebrafish embryos were anaesthetised in tricaine and fixed for 2h at room
197 temperature followed by overnight fixation at 4°C in 4% PFA, 0.1% glutaraldehyde in
198 0.1M sodium cacodylate buffer with 0.2M sucrose. Samples were rinsed in 0.1M sodium

199 cacodylate buffer and dehydrated in ethanol series (70% ethanol for 1h at 4°C; 90%
200 ethanol for 1h at 20°C; 100% ethanol for 1h at -20°C, twice). Samples were then
201 embedded in 50/50 LR White resin/ethanol for 1h at -20°C, followed by 70/30 LR White
202 resin/ethanol for 1h at -20°C and 100% LR White resin for 1h at -20°C. Samples were
203 then left overnight at -20°C in 100% LR White resin. Embryos were then placed in
204 capsules filled with LR White resin mixed with benzoin methyl ether (0.1 g in 100 ml LR
205 White), sealed, and placed in the oven for polymerization at 65°C for at least 72h.

206 70 nm ultrathin sections were cut with a Leica UC7 ultramicrotome and placed on
207 formvar-coated grids, which were then processed for gold labelled immunostaining.
208 Grids were treated with 0.15M glycine in PBS for 15 minutes, rinsed with PBS, followed
209 by Aurion blocking solution (Aurion, The Netherlands) for 15 minutes. Primary
210 antibodies were diluted in 0.1% BSA-c (Aurion, The Netherlands) at the following
211 concentrations: 1:25 mouse anti-PI(4,5)P₂; 1:10 mouse anti-PI(3,4)P₂; 1:10 mouse anti-
212 PI(3)P (Echelon Biosciences, Inc.). Samples were incubated with primary antibodies for
213 1h at room temperature. After rinsing the samples with PBS 5 x 5 minutes, these were
214 incubated with 10nm gold-conjugated goat anti-mouse secondary antibody (1:10;
215 Electron Microscope Sciences, Hatfield, PA) for 1h at room temperature. Samples were
216 then rinsed 5 x 5 minutes with PBS, treated with 2% glutaraldehyde (in PBS) for 5
217 minutes, rinsed 5 x 5 minutes with distilled water and air dried. Gold immunolabelled
218 samples were counter-stained with uranyl acetate and lead citrate and viewed with a
219 JEOL JEM 1200EX TEM (JEOL, Massachusetts, USA) (Electron Microscopy Facility at
220 the Laboratory of Pathology, The Hospital for Sick Children, Toronto). Images were

221 obtained using AmtV542 software, and were manipulated only for brightness and
222 contrast using Adobe Photoshop.

223

224 **Triad size measurement**

225 To determine total triad area ($A1+A2+A3$), the following features were measured: area
226 of T-tubule (A1), areas of the two terminal cisternae (A2, A3), the distance between the
227 membranes of the two terminal cisternae (D1) and the width of the gap between the
228 membrane of the terminal cisternae and the T-tubule membrane (*). Measurements
229 were done using the open source software Image J. Data and statistical analyses were
230 performed using GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA).

231

232 **Swim test and photoactivation assay**

233 All motor behaviour analysis was performed using Zebrabox software (Viewpoint,
234 France) as previously described (Sabha et al., 2016). To perform the photoactivation
235 assay, zebrafish were incubated for 5 min at 28.5°C with optovin 6b8 (ID 57051911;
236 ChemBridge), an optovin analog (Kokel et al., 2013). Optovin is a reversible TRPA1
237 ligand that elicits motor excitation following exposure to light. After incubation, the
238 Zebrabox platform monitored larvae for 20 second cycles over 10 minutes. Parameters
239 were set to capture 5 seconds of exposure to white light to elicit ambulatory movement,
240 followed by 15 seconds of recovery behaviour in the dark. This was repeated 30 times,
241 to get a total experiment time of 10 minutes. The average speed traveled during the 20

242 second cycle was used to compare groups (i.e., *cdipt* mutants vs. WT siblings). To
243 perform the spontaneous swim assay, zebrafish in system water were followed for 1
244 hour. Data were analyzed using statistics software (GraphPad Prism).

245

246 **Morpholino studies**

247 For knockdown of maternal *cdipt*, the following ATG-targeting MO was designed: 5'-
248 CCGAGAGTTTCTTTCTTTGGACGGA-3' (GeneTools LLC). An MO designed to a
249 random sequence (5'-CCTCTTACCTCAGTTACAATTTATA-3') with no homology by
250 Basic Local Alignment Search Tool (BLAST) analysis in the zebrafish genome was used
251 as a control (GeneTools LLC). Fertilized eggs were collected after timed matings of
252 adult zebrafish and injected at the 1-cell stage using a Picopump (World Precision
253 Instruments). Embryos were injected with concentrations ranging from 0.15 – 0.5 mM in
254 a volume of 1 nl.

256 **Results**

257

258 **Developing a new *cdipt* mutant zebrafish line**

259 Exon 3 of the *cdipt* gene was targeted using the CRISPR/Cas9 system (Fig 1B). A 10
260 bp deletion allele, hereafter referred to as *cdipt* mutant when present in homozygosity,
261 was identified after Sanger sequencing (Fig 1C). Due to lack of commercially available
262 antibodies against zebrafish CDIPT, we performed real-time PCR (qPCR) on total RNA
263 from whole embryos to confirm that *cdipt* transcript is reduced by this mutation. There
264 was a significant difference in *cdipt* mRNA levels between wildtype (WT) and mutants at
265 both 3 dpf and 6 dpf (Fig 1D) ($P < 0.05$, $n = 30$). This suggests that mutant *cdipt* mRNA
266 transcripts are being directed to the nonsense-mediated decay pathway, and is
267 consistent with this mutation being a loss of expression and function allele.

268

269 ***cdipt* zebrafish exhibit morphological and gastrointestinal** 270 **system abnormalities**

271 Homozygous *cdipt* mutant fish appeared phenotypically normal until 5 dpf, when
272 gastrointestinal system abnormalities are visible with bright-field microscopy. The
273 mutant phenotype is fully penetrant at 6 dpf and includes a dark, globular liver and small
274 intestine, partial deterioration of the ventral fin (folds, incisions, missing areas), tissue
275 degradation around the cloaca, and abnormal jaw structure (Fig 2A and S1 Fig). The

276 gastrointestinal features are reminiscent of the mutant *cdipt*^{hi559/hi559} phenotype, and
277 have already been well characterized (Thakur et al., 2011).

278

279 **Fig 2. Characterization of the *cdipt* mutant phenotype at 6dpf.**

280 **A)** *cdipt* mutant zebrafish exhibit a gastrointestinal phenotype with a dark,
281 globular and oversized liver (yellow outline) and a small intestine (yellow arrows),
282 abnormal jaw structure (black arrows), tissue degradation around the cloaca
283 (black arrowhead), and defective ventral fin (yellow arrowhead). **B)**
284 Representative image of *cdipt* mutants at 6dpf, showing normal birefringence
285 pattern indistinguishable from WT siblings, indicative of normal sarcomere
286 organization. **C)** Confocal micrographs showing localization by indirect
287 immunofluorescence of actin (upper panels), DHPR (middle panels) and α -
288 actinin (bottom panels) in the skeletal myofibers. There is no noticeable
289 difference in the localization of these proteins between WT (left column) and
290 *cdipt* mutant (right column). Insets represent high magnification of areas
291 surrounded by white rectangles. Scale bars = 5 μ m.

292

293 ***cdipt* zebrafish have generally normal muscle structure**

294 Gross morphology of *cdipt* zebrafish muscle was investigated using birefringence.
295 Birefringence uses polarized light to assess muscle integrity. Organized skeletal muscle
296 will appear bright amidst a dark background when visualized between two polarized
297 light filters, whereas disorganized muscle exhibits degenerative dark patches and an

298 overall decrease in brightness in some myotomes. Based on birefringence analysis,
299 *cdipt* zebrafish have normal muscle integrity and sarcomere organization at all ages
300 examined (Fig 2B).

301 We next studied the localization of several sarcomeric proteins, such as actin, myosin
302 (contractile proteins), dihydropyridine receptor (DHPR), ryanodine receptor type 1
303 (RyR1) and junctin (markers for triads), laminin and dystrophin (markers for
304 myotendinous junctions), and α -actinin (a Z-line marker). Immunostaining with
305 antibodies against these proteins on myofibers isolated from 6dpf zebrafish showed no
306 differences in localization between WT and *cdipt* mutants (Fig 2C and S2 Fig),
307 indicating no qualitative defects in the formation and organization of key muscle
308 structures.

309 We next studied the ultrastructure of muscle, given that abnormal triad formation is a
310 hallmark of many PIP-related myopathies and may not be appreciated by light
311 microscopy. *cdipt* larvae and their WT siblings were thus processed at 6 dpf for
312 transmission electron microscopy. Electron micrographs revealed no major
313 abnormalities in triad structure in *cdipt* mutants (Fig 3A,B). To better characterize the
314 triads we measured the area of T-tubules (A1), the areas of the two terminal cisternae
315 (A2, A3), total triad area (A1+A2+A3), the distance between the membranes of the two
316 terminal cisternae of the sarcoplasmic reticulum (D1), and the width of the gap between
317 the T-tubule and each of the two terminal cisternae (*), where the junctional feet
318 corresponding to the ryanodine receptor-dihydropyridine receptor complex are found
319 (Al-Qusairi and Laporte, 2011) (Fig 3C). There was no significant difference in the total
320 area of the triad (A1+A2+A3) (Fig 3D). However, the T-tubule area (A1) was

321 qualitatively slightly smaller in the *cdipt* mutant as compared to WT, and the distance
322 between terminal cisternae at maximum distance (D1) and the gap width (*) were
323 quantitatively and significantly smaller in *cdipt* mutants (Fig 3D).

324

325 **Fig 3. Skeletal muscle ultrastructure.**

326 **A-B)** Transmission electron micrographs show normal skeletal muscle
327 ultrastructure in *cdipt* larvae. T-tubules (insets; black arrow) are apposed by
328 terminal cisternae of sarcoplasmic reticulum (insets; white arrow). **C)** Diagram
329 illustrating triad structure and features used for measurements: A1 = T-tubule
330 area; A2 and A3 = terminal cisternae (TC) areas; D1 = maximum distance
331 between TCs; * = gap width (distance between TC membrane and T-tubule
332 membrane). **D)** There is no significant difference in the triad area between WT
333 and *cdipt* mutant larvae (A1+A2+A3 graph) (n = 36, p = 0.9217). The T-tubule
334 area (A1 graph) is qualitatively slightly smaller in the *cdipt* mutant than in WT
335 (n=36; P=0.5246), whereas the distance between cisternae at maximum distance
336 (D1 graph) (n = 36, p < 0.0001) and the gap width (* graph) (n = 44, p < 0.0001)
337 are significantly smaller in *cdipt* mutants than in WT. Scale bars = 200 nm.

338

339 ***cdipt* zebrafish have abnormal motor behaviour as compared** 340 **to wildtype siblings**

341 Given the subtle but significant change observed in the appearance of the triad, we
342 wanted to determine if there was any alteration in muscle function. To assess muscle

343 function, we performed a spontaneous swim test assay and a routine photoactivation
344 movement assay previously utilized by our lab (Sabha et al., 2016). The latter involved
345 incubating zebrafish larvae with a molecule called optovin 6b8, which when exposed to
346 white light, will activate zebrafish muscle through a reflex arc. If muscle function is
347 impaired, mutants will have reduced movement when compared to WT. We did thirty
348 rounds of 20 second-activation periods to assess both the speed of movement and
349 muscle fatigue. The average speed of movement was significantly lower in *cdipt* mutant
350 zebrafish both in the spontaneous swim test (Fig 4A,B) and in their response to optovin
351 (Fig 4C,D). In addition, *cdipt* mutants spent less time moving (S3A Fig) and covered
352 shorter distances than their WT siblings (S3B Fig). The rate of fatigue, however, was
353 similar in the *cdipt* mutant and WT zebrafish (Fig 4D).

354

355 **Fig 4. *cdipt* mutants have significantly impaired motor function compared**
356 **to their wildtype siblings.**

357 **A)** Spontaneous swim movement was assessed by tracking 5-days or 6-days old
358 zebrafish larvae over 1 hour. Representative examples of tracking plots of
359 individual larvae movement. Black represents slow movement (<5 mm/s), green
360 represents average speed (5-20 mm/s), and red represents fast movement (>20
361 mm/s). **B)** The *cdipt* mutant larvae are significantly slower than their WT siblings,
362 both at 5dpf (WT n = 22, *cdipt* n = 26, p = 0.0318) and 6dpf (WT n = 36, *cdipt* n =
363 28, p = 0.0036). **C)** Involuntary motor function was assessed using an optovin-
364 stimulated movement assay in response to pulses of light. Representative
365 examples of tracking plots of individual larvae showing movement over 20

366 seconds, involving 5 seconds of white light exposure followed by 15 seconds of
367 darkness. **D)** There is a significant difference between the average speed
368 travelled by WT zebrafish compared to *cdipt* mutant zebrafish (n = 18 and 14,
369 respectively; p < 0.0001, Student's *t* test, 2-tailed). WT and *cdipt* mutant
370 zebrafish plateau at the same rate (n = 7, p=0.3487).

371

372 ***cdipt* zebrafish do not show changes in the localization of**

373 **PIPs**

374 Given that CDIPT is the rate-limiting enzyme for PI synthesis (the precursor for all
375 PIPs), we looked at the expression and localization of several species of PIPs in
376 myofibers. We specifically investigated PI3P, PI(3,4)P2 and PI(4,5)P2 localization.
377 PI(4,5)P2 and PI(3,4)P2 are found mostly at the plasma membrane, whereas PI3P is
378 mostly found on endosomes (Viaud et al., 2016). Immunofluorescence staining with
379 anti-PIP antibodies revealed no significant differences in the localization of PI(4,5)P2,
380 PI3P, PI(3,4)P2 (Fig 5). To further investigate PI(4,5)P2 localization in *cdipt* larvae *in*
381 *vivo*, a fluorescent marker for PI(4,5)P2 (PLC δ PH-GFP) was injected into 1-cell stage
382 *cdipt* embryos. At 6 dpf, PI(4,5)P2 appeared to properly localize to the plasma
383 membrane (Fig 5A,A'). These results were further supported by immunoelectron
384 microscopy studies. Nanogold-labelled antibodies against PI3P, PI(3,4)P2 and
385 PI(4,5)P2 localized at the triad and its vicinity and showed similar localization pattern in
386 WT and *cdipt* mutant embryos (Fig 6).

387

388 **Fig 5. Localization of PIPs by immunofluorescence in wildtype and *cdipt***
389 **mutant zebrafish.**

390 Confocal micrographs showing localization of PIPs is not affected in early larval
391 development of *cdipt* mutants. **(A, A')** visualization of skeletal muscle from live
392 embryos injected with PLC δ PH-GFP, a marker for PI(4,5)P₂. There was no
393 obvious difference in expression between wild type (WT) and *cdipt* mutant
394 embryos. **(B-D, B'-D')** Immunostaining with PIP antibodies of myofibers isolated
395 from WT and *cdipt* mutants. Localization of PI(4,5)P₂ **(B, B')**, PI3P **(C, C')** and
396 PI(3,4)P₂ **(D, D')** is similar in wildtype and *cdipt* zebrafish. Scale bars = 10 μ m.

397

398 **Fig 6. Localization of PIPs by immunoelectron microscopy in wildtype and**
399 ***cdipt* mutant zebrafish.**

400 Transmission immunoelectron micrographs showing localization of nanogold-
401 labelled antibodies against **(A, A')** PI(4,5)P₂, **(B, B')** PI(3,4)P₂ and PI3P **(C, C')**
402 (yellow arrowheads) at the skeletal muscle triad. There is no difference in
403 localization of these antibodies between WT and *cdipt* mutant embryos. Scale
404 bar = 100nm.

405

406 **Maternal *cdipt* mRNA and/or PI are sufficient for normal**
407 **muscle development**

408 Given the importance of CDIPT in generating a precursor to all PIP species, it is
409 surprising that there is no developmental phenotype in skeletal muscle. However, a
410 previously published lipidomic analysis of the early zebrafish yolk found that PI is
411 already present at 0 hpf (Fraher et al., 2016) and previous results on *cdipt*^{hi559/hi559}
412 zebrafish (Thakur et al., 2011) and our qPCR results (see Fig 1D) show there is
413 maternal *cdipt* mRNA expression in early stages of the zebrafish embryo before zygotic
414 gene expression is turned on.

415 To prevent production of CDIPT protein from maternal mRNA, we injected zebrafish
416 embryos at one-cell stage with a translation blocking morpholino (ATG-MO). Injection of
417 *cdipt* ATG-MO at both 0.3 mM and 0.5 mM caused increased levels of embryo death
418 (S4A Fig), suggesting that blocking of maternal *cdipt* mRNA translation is broadly
419 detrimental for embryogenesis. While we were not able to study muscle in the majority
420 of *cdipt* ATG morphants due to early lethality, some morphants did survive beyond the
421 first day post fertilization (S4B Fig). In those morphants, the skeletal muscle
422 development was not obviously affected.

423 To investigate whether maternally deposited PI in the yolk can be delivered to
424 developing skeletal muscle, we injected BODIPY-labelled PI into yolk at the one-cell
425 stage. Fluorescence was tracked with a confocal microscope over several days. By 1
426 dpf, the fluorescent probes appeared in the skeletal muscle compartment (S5 Fig).
427 Fluorescence was not detectable at 2 days post-injection and later. These results
428 suggest that PI present in the yolk at early stages can be delivered to skeletal muscle.
429 Taken together, our data suggest that the presence of maternally deposited mRNA in
430 the cell and/or PI in the yolk fulfill the early developmental requirements for CDIPT and

431 for PI, which is consistent with the lack of a phenotype until the yolk is depleted at 5 dpf.
432 This also suggests that once PI and its PIP derivatives are generated, they likely persist
433 as a stable pool in skeletal muscle.

434 Discussion

435 To investigate the role of PIPs in muscle development, we developed and characterized
436 a new *cdipt* mutant zebrafish. This mutant showed defects in fin morphology and
437 aberrant swimming behaviour, in addition to the gastrointestinal defects previously
438 reported in another *cdipt* mutant [*cdipt*^{hi559/hi559}, (Thakur et al., 2011)].

439 The purpose of generating this model was to determine how the potential loss of all
440 seven PIP species would affect muscle development. We expected that loss of CDIPT
441 and the subsequent depletion of PI would have severe effects on skeletal muscle;
442 however, mutant *cdipt* larvae showed only minimal abnormalities in muscle structure
443 and overall muscle function. We hypothesize that this modest phenotype is the result of
444 PI deposited in the muscle during embryogenesis that then provides sufficient substrate
445 for generation and maintenance of PIP species at subsequent developmental stages.

446 Given the importance of CDIPT in generating a precursor to all PIP species, it is
447 surprising that there is no significant adverse phenotype in muscle. The lack of
448 widespread abnormalities may be because *cdipt* mRNA and PIs are maternally
449 deposited into zebrafish yolk. Depletion of maternal mRNA using a translation-blocking
450 morpholino resulted in increased mortality in the zebrafish, consistent with a role for
451 CDIPT and de novo PI synthesis in embryogenesis. However, the impact of the
452 translation-blocking morpholino did not seem to affect skeletal muscle development in
453 the surviving injected embryos, suggesting that maternally deposited CDIPT does not
454 play a role in myogenesis. There is likely also an important contribution to total embryo
455 PI from maternal deposition of this precursor lipid in the yolk. In order to remove this

456 potential confounder to the assessment of CDIPT function in skeletal muscle, we would
457 need to prevent the deposition of PI into the yolk, or develop a method of depleting yolk
458 PI without disrupting other essential nutrients contained within the yolk. Currently, there
459 are no technologies that would allow us to complete either of those experiments. We
460 attempted to use direct lipase injection into the yolk in order to deplete it, but this
461 resulted in embryonic lethality prior to myogenesis.

462 The one part of the muscle where we did observe abnormalities was the triad. We
463 showed by immunofluorescence that several species of PIPs localize to the sarcomere.
464 Moreover, our novel immunoelectron microscopy studies showed these molecules
465 localize to the triad. To our knowledge, this is the first report on ultrastructural
466 localization of PI3P, PI(3,4)P2 and PI(4,5)P2 at the triad in a vertebrate model, as
467 previous studies focused on culture cells (Watt et al., 2002) (Tabellini et al., 2003)
468 (Mayhew et al., 2004) (Wegner et al., 2014) (Pastorek et al., 2016). Our data add to the
469 growing evidence showing the importance of PIP metabolism in the development and
470 maintenance of this key muscle substructure. Work with mammalian myocytes in culture
471 has implicated PIP2 (via its binding to BIN1) in the formation of the T-tubule. While we
472 did not see an overall decrease in PIP2 levels, nor in its localization, it is tempting to
473 speculate that the loss of CDIPT sufficiently impacted PIP synthesis enough to result in
474 mild by critical reductions in PIP2 that were enough to alter triad formation. Future
475 studies will be required to fully explore this relationship.

476 Of note, phenotypic abnormalities in *cdipt* mutants do not appear until 5 dpf, shortly
477 after the yolk has been depleted. The most prominent of these is the digestive system
478 phenotype, likely reflecting a requirement for *de novo* PIP synthesis in this organ

479 system, since pools of PI are locally made and used almost immediately after synthesis
480 (Varnai and Balla, 2006). However, because skeletal muscle has no phenotype at 5 dpf
481 and previous data has shown that *cdipt* mRNA is not present in skeletal muscle after 5
482 dpf (Varnai and Balla, 2006), it is possible that maturing skeletal muscle does not
483 require *de novo* PIP synthesis. Instead, perhaps PIPs are maintained in pools that can
484 fluctuate between the different species when needed. Alternatively, a requirement for
485 PIP synthesis in muscle may not manifest in the window of time after yolk depletion and
486 before mutant death, but may develop as the muscle continues to grow and mature.
487 Muscle specific targeting of *cdipt* would be helpful in the future to distinguish between
488 these possibilities.

489 Of note, the most obvious phenotypes in the *cdipt* mutants are in the liver,
490 gastrointestinal system, and the fin. Interestingly, these phenotypes of the *cdipt* mutants
491 are also visible in *mtm1* mutant zebrafish (Sabha et al., 2016). The fact that two
492 mutated PIP-related genes cause similar defects suggest that PIP metabolism must be
493 tightly regulated in these tissues in zebrafish development, and that there is an
494 increased requirement for *de novo* synthesis and homeostatic balance.

495

496 **Acknowledgements**

497 The authors gratefully thank Jonathan Volpatti, Yukari Endo and Mo Zhao (Dowling
498 Lab) for useful discussions and insightful suggestions; Evangelina Aristegui for technical
499 support; Scott Knox, Alejandro Salazar, and Elyjah Schimmens for zebrafish care
500 (SickKids Zebrafish Facility); Paul Paroutis and Kimberley Lau for technical support
501 (SickKids Imaging Facility); and Doug Holmyard, Ali Darbandi and William Martin
502 (SickKids Nanoscale Biomedical Imaging Facility) for help with TEM and immunoEM
503 sample preparation. The authors also thank the following people for generously
504 providing reagents: Angela Dulhunty (John Curtin School of Medical Research,
505 Australian National University, Canberra, Australia) for anti-Junctin antibody; Tobias
506 Meyer Lab (Stanford University, CA) for the PLC- δ PH-GFP construct; Sergio Grinstein
507 and Julie Brill (The Hospital for Sick Children, Toronto, Canada) for PIP constructs and
508 for helpful discussion.

509 References

- 510 Al-Qusairi, L., and J. Laporte. 2011. T-tubule biogenesis and triad formation in skeletal muscle
511 and implication in human diseases. *Skelet Muscle*. 1:26.
- 512 Amoasii, L., D.L. Bertazzi, H. Tronchere, K. Hnia, G. Chicanne, B. Rinaldi, B.S. Cowling, A. Ferry, B.
513 Klaholz, B. Payrastre, J. Laporte, and S. Friant. 2012. Phosphatase-dead myotubularin
514 ameliorates X-linked centronuclear myopathy phenotypes in mice. *PLoS Genet*.
515 8:e1002965.
- 516 Balla, T. 2013. Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation.
517 *Physiological Reviews*. 93:1019-1137.
- 518 Bunney, T.D., and M. Katan. 2010. Phosphoinositide signalling in cancer: beyond PI3K and PTEN.
519 *Nat Rev Cancer*. 10:342-352.
- 520 De Camilli, P., S.D. Emr, P.S. McPherson, and P. Novick. 1996. Phosphoinositides as regulators in
521 membrane traffic. *Science*. 271:1533-1539.
- 522 De Matteis, M.A., and A. Godi. 2004. PI-loting membrane traffic. *Nat Cell Biol*. 6:487-492.
- 523 Dowling, J.J., M.W. Lawlor, and R.T. Dirksen. 2014. Triadopathies: an emerging class of skeletal
524 muscle diseases. *Neurotherapeutics*. 11:773-785.
- 525 Dowling, J.J., A.P. Vreede, S.E. Low, E.M. Gibbs, J.Y. Kuwada, C.G. Bonnemann, and E.L.
526 Feldman. 2009. Loss of Myotubularin Function Results in T-Tubule Disorganization in
527 Zebrafish and Human Myotubular Myopathy. *PLoS Genetics*. 5:e1000372.
- 528 Fraher, D., A. Sanigorski, N.A. Mellett, P.J. Meikle, A.J. Sinclair, and Y. Gibert. 2016. Zebrafish
529 Embryonic Lipidomic Analysis Reveals that the Yolk Cell Is Metabolically Active in
530 Processing Lipid. *Cell Rep*. 14:1317-1329.
- 531 Frost, A., V.M. Unger, and P. De Camilli. 2009. The BAR domain superfamily: membrane-
532 molding macromolecules. *Cell*. 137:191-196.
- 533 Gibbs, E.M., E.J. Horstick, and J.J. Dowling. 2013. Swimming into prominence: the zebrafish as a
534 valuable tool for studying human myopathies and muscular dystrophies. *FEBS J*.
535 280:4187-4197.
- 536 Gonorazky, H.D., C.G. Bonnemann, and J.J. Dowling. 2018. The genetics of congenital
537 myopathies. *In Handbook of Clinical Neurology*. Vol. 148. Elsevier. 549-564.
- 538 Horstick, E.J., E.M. Gibbs, X. Li, A.E. Davidson, and J.J. Dowling. 2013. Analysis of embryonic and
539 larval zebrafish skeletal myofibers from dissociated preparations. *J Vis Exp*:e50259.
- 540 Jungbluth, H., S. Treves, F. Zorzato, A. Sarkozy, J. Ochala, C. Sewry, R. Phadke, M. Gautel, and F.
541 Muntoni. 2018. Congenital myopathies: disorders of excitation-contraction coupling and
542 muscle contraction. *Nat Rev Neurol*. 14:151-167.
- 543 Kokel, D., C.Y. Cheung, R. Mills, J. Coutinho-Budd, L. Huang, V. Setola, J. Sprague, S. Jin, Y.N. Jin,
544 X.P. Huang, G. Bruni, C.J. Woolf, B.L. Roth, M.R. Hamblin, M.J. Zylka, D.J. Milan, and R.T.
545 Peterson. 2013. Photochemical activation of TRPA1 channels in neurons and animals.
546 *Nat Chem Biol*. 9:257-263.
- 547 Lo Vasco, V.R. 2018. The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of
548 Alzheimer's Disease. *Curr Alzheimer Res*. 15:355-362.

- 549 Lykidis, A., P.D. Jackson, C.O. Rock, and S. Jackowski. 1997. The role of CDP-diacylglycerol
550 synthetase and phosphatidylinositol synthase activity levels in the regulation of cellular
551 phosphatidylinositol content. *J Biol Chem.* 272:33402-33409.
- 552 Ma, A.C., Y. Chen, P.R. Blackburn, and S.C. Ekker. 2016. TALEN-Mediated Mutagenesis and
553 Genome Editing. *Methods Mol Biol.* 1451:17-30.
- 554 Mayhew, T.M., G. Griffiths, and J.M. Lucocq. 2004. Applications of an efficient method for
555 comparing immunogold labelling patterns in the same sets of compartments in different
556 groups of cells. *Histochem Cell Biol.* 122:171-177.
- 557 Nance, J.R., J.J. Dowling, E.M. Gibbs, and C.G. Bonnemann. 2012. Congenital myopathies: an
558 update. *Curr Neurol Neurosci Rep.* 12:165-174.
- 559 Nicholson, G., G.M. Lenk, S.W. Reddel, A.E. Grant, C.F. Towne, C.J. Ferguson, E. Simpson, A.
560 Scheuerle, M. Yasick, S. Hoffman, R. Blouin, C. Brandt, G. Coppola, L.G. Biesecker, S.D.
561 Batish, and M.H. Meisler. 2011. Distinctive genetic and clinical features of CMT4J: a
562 severe neuropathy caused by mutations in the PI(3,5)P(2) phosphatase FIG4. *Brain.*
563 134:1959-1971.
- 564 Pastorek, L., M. Sobol, and P. Hozak. 2016. Colocalization coefficients evaluating the
565 distribution of molecular targets in microscopy methods based on pointed patterns.
566 *Histochem Cell Biol.* 146:391-406.
- 567 Peter, B.J., H.M. Kent, I.G. Mills, Y. Vallis, P.J. Butler, P.R. Evans, and H.T. McMahon. 2004. BAR
568 domains as sensors of membrane curvature: the amphiphysin BAR structure. *Science.*
569 303:495-499.
- 570 Sabha, N., J.R. Volpatti, H. Gonorazky, A. Reifler, A.E. Davidson, X. Li, N.M. Eltayeb, C. Dall'Armi,
571 G. Di Paolo, S.V. Brooks, A. Buj-Bello, E.L. Feldman, and J.J. Dowling. 2016. PIK3C2B
572 inhibition improves function and prolongs survival in myotubular myopathy animal
573 models. *J Clin Invest.* 126:3613-3625.
- 574 Tabellini, G., R. Bortul, S. Santi, M. Riccio, G. Baldini, A. Cappellini, A.M. Billi, R. Berezney, A.
575 Ruggeri, L. Cocco, and A.M. Martelli. 2003. Diacylglycerol kinase-theta is localized in the
576 speckle domains of the nucleus. *Exp Cell Res.* 287:143-154.
- 577 Thakur, P.C., C. Stuckenholtz, M.R. Rivera, J.M. Davison, J.K. Yao, A. Amsterdam, K.C. Sadler, and
578 N. Bahary. 2011. Lack of de novo phosphatidylinositol synthesis leads to endoplasmic
579 reticulum stress and hepatic steatosis in cdipt-deficient zebrafish. *Hepatology.* 54:452-
580 462.
- 581 Varnai, P., and T. Balla. 2006. Live cell imaging of phosphoinositide dynamics with fluorescent
582 protein domains. *Biochim Biophys Acta.* 1761:957-967.
- 583 Viaud, J., R. Mansour, A. Antkowiak, A. Mujalli, C. Valet, G. Chicanne, J.M. Xuereb, A.D. Terrisse,
584 S. Severin, M.P. Gratacap, F. Gaits-Iacovoni, and B. Payrastre. 2016. Phosphoinositides:
585 Important lipids in the coordination of cell dynamics. *Biochimie.* 125:250-258.
- 586 Volpatti, J.R., A. Al-Maawali, L. Smith, A. Al-Hashim, J.A. Brill, and J.J. Dowling. 2019. The
587 expanding spectrum of neurological disorders of phosphoinositide metabolism. *Dis*
588 *Model Mech.* 12.
- 589 Watt, S.A., G. Kular, I.N. Fleming, C.P. Downes, and J.M. Lucocq. 2002. Subcellular localization of
590 phosphatidylinositol 4,5-bisphosphate using the pleckstrin homology domain of
591 phospholipase C delta1. *Biochem J.* 363:657-666.

592 Wegner, C.S., K.O. Schink, H. Stenmark, and A. Brech. 2014. Monitoring phosphatidylinositol 3-
593 phosphate in multivesicular endosome biogenesis. *Methods Enzymol.* 534:3-23.
594

595 **Supplemental material**

596 **Fig. S1. Phenotypic variations in *cdipt* mutants. A-B)** Examples of fin degeneration
597 (yellow arrowheads), oversized liver (yellow outline), and abnormal jaw structure (black
598 arrows) in *cdipt* mutant zebrafish. **C)** Many *cdipt* mutants have partially folded ventral
599 fin.

600 **Fig. S2. Localization of triad-associated proteins in the muscle.** Confocal
601 micrographs showing localization by indirect immunofluorescence of RyR1 (top panels)
602 and Junctin (bottom panels) in skeletal myofibers. There is no noticeable difference in
603 localization of these proteins in WT (left panels) and *cdipt* mutant (right panels). Scale
604 bars = 10 μ m.

605 **Fig. S3. *cdipt* mutants have impaired motor function. A)** *Cdipt* mutant zebrafish
606 spend significantly less time swimming compared to their WT siblings, both at 5dpf (WT
607 $n = 22$, *cdipt* $n = 26$, $p = 0.0359$) and 6dpf (WT $n = 36$, *cdipt* $n = 28$, $p = 0.0209$). **B)**
608 *Cdipt* mutant zebrafish travel significantly shorter distances compared to their WT
609 siblings at 5dpf (WT $n = 22$, *cdipt* $n = 26$, $p = 0.0121$) whereas at 6dpf the travelled
610 distances are not significantly different (WT $n = 36$, *cdipt* $n = 28$, $p = 0.1015$).

611 **Fig. S4. Blocking maternal *cdipt* mRNA translation is detrimental for**
612 **embryogenesis. A)** Embryos injected with ATG-MO ($n=115$) show significantly higher
613 mortality rates than those injected with Ctrl-MO ($n=117$). **B)** Surviving ATG-MO-injected
614 *cdipt* embryos have a normal birefringence pattern indistinguishable from their WT
615 siblings.

616 **Fig. S5. Maternally deposited PI in the yolk is transported to the muscle.** Zebrafish
617 larvae at 1 dpf after injection of BODIPY-PI into yolk at the 1-cell stage (arrows indicate
618 accumulation of fluorescently-labeled PI in the muscle).

Figure 1




Figure 2




Figure 3






Figure 4







Figure 5




Figure 6

